Xylitol is a sugar alcohol widely used as a low‑calorie sweetener in processed foods, sugar‑free chewing gum, and toothpaste. Manufacturers favor it because it adds sweetness without the calories or tooth‑decay risk associated with sugar.
Previous work by the study team showed that xylitol can enhance platelet clot formation and that elevated blood xylitol levels were associated with cardiovascular events in high‑risk individuals over a three‑year period. The new research presented at the European Society of Cardiology Congress 2026 aimed to determine whether similar associations exist in the general population.
The investigators analyzed data from two large observational cohorts in North America and Europe. Combined, the studies included 17,710 participants with a mean age of 60.9 years.
The cohorts were:
The article did not report specific plasma concentration cutoffs used to define the xylitol groups.
Participants in each cohort were stratified into four groups based on measured plasma xylitol levels. The researchers adjusted analyses for traditional cardiovascular risk factors, including age, smoking status, diabetes, high blood pressure, and body mass index.
After these adjustments, the team compared incidence of major adverse cardiovascular events across xylitol groups. The article reports that the association persisted after accounting for these confounders, but it does not provide full details of model covariates, effect estimates beyond the headline percentages, or the exact statistical methods in the text provided.
In the CLSA cohort (6‑year follow‑up), participants with the highest blood xylitol levels had a 57% higher risk of a major adverse cardiovascular event (MACE) compared with those with the lowest levels.
In EPIC‑Norfolk (30‑year follow‑up), the group with the highest xylitol levels had an 18% higher risk of MACE relative to the lowest group.
When pooled, the researchers observed that rising xylitol levels corresponded with increasing incidence of heart attack, stroke, and cardiovascular death.
The combined analysis demonstrated a dose‑dependent relationship: as plasma xylitol increased, so did the occurrence of MACE. The association was reported to be independent of other factors that contribute to cardiovascular risk and of the likelihood of using artificial sweeteners.
Specifically, the article notes the association remained after adjustment for body mass index, diabetes, and hypertension. The source did not publish exact threshold values, hazard ratios beyond the two cohort figures, or subgroup analyses in the text provided.
Commenting on the findings, a member of the European Society of Cardiology Communication Committee observed that artificial sweeteners have generally favorable safety ratings from regulatory authorities but that this observational work suggests xylitol may have negative long‑term cardiovascular effects in the general population.
An external expert not involved in the study—Stanley Hazen, MD, PhD—highlighted a growing body of research indicating that sugar alcohols such as xylitol and erythritol may increase risk for clotting events like heart attack and stroke. He reported that he advises his patients, particularly those with cardiovascular disease or higher risk, to avoid these non‑nutritive sweeteners. The article presents these comments as expert opinion rather than new trial evidence.
Clinicians quoted in the article noted a practical role for artificial sweeteners in diabetes management because they tend to produce smaller immediate rises in blood glucose than sucrose. However, they cautioned that blunting a short‑term glucose spike does not necessarily translate to long‑term health benefit.
One cardiologist recommended choosing naturally sweet whole foods, such as fruit, which provide fiber and other nutrients alongside sweetness. The source emphasizes weighing short‑term glycemic effects against overall dietary quality and long‑term outcomes.
The investigators concluded that their long‑term findings in the general population underscore limited knowledge about the cardiovascular safety of xylitol and call for further research. They noted concern is timely because the amount of xylitol in consumer products is increasing.
The article did not report mechanistic trial data, specific plasma thresholds for harm, or randomized trial evidence establishing causality. As such, the current findings describe an adjusted association between plasma xylitol levels and higher incidence of major adverse cardiovascular events (MACE), but they do not prove cause and effect. Further studies are warranted to replicate results, clarify mechanisms (including the role of platelet effects), and determine clinical recommendations.